Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · IEX Real-Time Price · USD
27.65
-0.20 (-0.72%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Myriad Genetics Revenue
Myriad Genetics had revenue of $202.20M in the quarter ending March 31, 2024, with 11.59% growth. This brings the company's revenue in the last twelve months to $774.20M, up 11.44% year-over-year. In the year 2023, Myriad Genetics had annual revenue of $753.20M with 11.03% growth.
Revenue (ttm)
$774.20M
Revenue Growth
+11.44%
P/S Ratio
3.21
Revenue / Employee
$286,741
Employees
2,700
Market Cap
2.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
| Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
| Dec 31, 2021 | 690.60M | 133.60M | 23.99% |
| Dec 31, 2020 | 557.00M | -81.60M | -12.78% |
| Jun 30, 2020 | 638.60M | -212.50M | -24.97% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| QuidelOrtho | 2.86B |
| Evolent Health | 2.18B |
| Integra LifeSciences Holdings | 1.53B |
| Astrana Health | 1.45B |
| Certara | 360.69M |
| Protagonist Therapeutics | 314.95M |
| Vericel | 207.78M |
| Intellia Therapeutics | 52.60M |
MYGN News
- 15 days ago - Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing - GlobeNewsWire
- 24 days ago - Myriad Genetics Earns 2024 Great Place To Work® Certification™ - GlobeNewsWire
- 4 weeks ago - Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election - GlobeNewsWire
- 7 weeks ago - Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool - GlobeNewsWire
- 2 months ago - QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications - GlobeNewsWire
- 2 months ago - Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting - GlobeNewsWire
- 2 months ago - New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer - GlobeNewsWire
- 2 months ago - Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA - GlobeNewsWire